InflaRx NV (FRA:IF0) ROE % Adjusted to Book Value: -41.33% (As of Mar. 2026)

InflaRx NV FRA:IF0 +32.47% 31 ROE % Adjusted to Book Value is -41.33% as of Mar. 2026. GuruFocus rates FRA:IF0 with a GF Score™ of 31/100. The stock has 5 warning signs investors should review.

InflaRx NV's ROE % for the quarter that ended in Mar. 2026 was -57.04%. InflaRx NV's PB Ratio for the quarter that ended in Mar. 2026 was 1.38. InflaRx NV's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was -41.33%.

InflaRx NV ROE % Adjusted to Book Value Related Terms

InflaRx NV ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for InflaRx NV's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

InflaRx NV ROE % Adjusted to Book Value Chart

InflaRx NV Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

-30.76

-22.56

-50.78

-22.29

-57.18

InflaRx NV Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															-55.42	-108.98	-58.05	-63.19	-41.33

FRA:IF0 vs BCYC, ELDN, ZNTL: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, InflaRx NV's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

InflaRx NV ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, InflaRx NV's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where InflaRx NV's ROE % Adjusted to Book Value falls into.

Save Embed

31GF Score

InflaRx NV FRA:IF0

ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

InflaRx NV ROE % Adjusted to Book Value Calculation

InflaRx NV's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-88.63%	/	1.55
	=	-57.18%

InflaRx NV's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-57.04%	/	1.38
	=	-41.33%

Frequently Asked Questions Learn more about ROE % Adjusted to Book Value →

What does a ROE % Adjusted to Book Value of -41.33% mean?

InflaRx NV (FRA:IF0) has a ROE % Adjusted to Book Value of -41.33% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on InflaRx NV and its competitors.

Is InflaRx NV's ROE % Adjusted to Book Value too high?

InflaRx NV's current ROE % Adjusted to Book Value is -41.33%. Overall, InflaRx NV has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.

How does InflaRx NV's ROE % Adjusted to Book Value compare to BCYC and ELDN?

InflaRx NV's ROE % Adjusted to Book Value of -41.33% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROE % Adjusted to Book Value for a Biotechnology company?

A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROE % Adjusted to Book Value mean?

A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on InflaRx NV and its competitors. InflaRx NV's current ROE % Adjusted to Book Value is -41.33%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is InflaRx NV stock overvalued right now?

InflaRx NV (FRA:IF0) has a current ROE % Adjusted to Book Value of -41.33%. The current ROE % Adjusted to Book Value is -41.33%. InflaRx NV's overall GF Score™ is 31/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROE % Adjusted to Book Value calculated?

ROE % Adjusted to Book Value is calculated from a company's financial statements. For InflaRx NV (FRA:IF0), the current ROE % Adjusted to Book Value is -41.33% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

InflaRx NV Business Description

Industry Healthcare Biotechnology

Comparable Companies BCYC ELDN ZNTL RNAC GLSI SABS SRZN LYEL ALXO CNXU VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Other Exchanges IFRX:USA

Address Winzerlaer Strasse 2, Jena, DEU, 07745

Website https://www.inflarx.de

InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

31GF Score

Get the complete analysis for FRA:IF0

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.04

Price

View FRA:IF0 Analysis

See ROE % Adjusted to Book Value data for all stocks →